Published in Oncotarget on December 01, 2015
The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer (2016) 0.95
Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res (2016) 0.76
The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer (2016) 0.76
Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division. J Biol Chem (2016) 0.75
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. Oncotarget (2016) 0.75
Surfing the p53 network. Nature (2000) 35.36
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell (1997) 17.78
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
Emerging roles of caspase-3 in apoptosis. Cell Death Differ (1999) 8.05
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol (2014) 2.84
Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res (2001) 2.42
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene (2004) 2.30
A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol (2009) 2.16
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 1.74
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des (2000) 1.42
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27
Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase. Biochem Biophys Res Commun (1998) 1.22
Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ (2010) 1.21
Cell cycle control as a basis for cancer drug development (Review). Int J Oncol (2000) 1.16
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res (2013) 1.12
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol (2008) 1.12
Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate (2012) 1.10
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene (2012) 1.08
Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res (2008) 1.06
Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem (2010) 1.04
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 1.03
A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. Biochem J (2012) 1.01
Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol (2008) 0.98
Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther (2014) 0.94
Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res (2008) 0.93
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget (2014) 0.92
Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms. Curr Pharm Des (2011) 0.84